Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]
News [4645]
Articles [192]
Editorials [8]
Conferences [136]
elearning [9]
Centrosomes in ovarian cancer
Dr Fanni Gergely - CRUK Cambridge Institute
Centrosomes in ovarian cancer ( Dr Fanni Gergely - CRUK Cambridge Institute )
27 Apr 2017
Hallmarks of cancer cell development
Dr Douglas Hanahan - Swiss Institute for Experimental Cancer Research, Lausanne...
Hallmarks of cancer cell development ( Dr Douglas Hanahan - Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland )
27 Apr 2017
What is the WIN Consortium?
Dr John Mendelsohn - Chairman of the WIN Consortium
What is the WIN Consortium? ( Dr John Mendelsohn - Chairman of the WIN Consortium )
27 Apr 2017
Pembrolizumab and indoximod for melanoma
Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of...
Pembrolizumab and indoximod for melanoma ( Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA )
13 Apr 2017
Projections of cancer incidence and burden among the HIV-positive population in...
Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA
Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030 ( Jessica Yasmine Islam - University of North Carolina, Chapel Hill, USA )
12 Apr 2017
Nivolumab for NSCLC: five years on
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Nivolumab for NSCLC: five years on ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Avelumab for metastatic Merkel cell carcinoma after chemotherapy
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Avelumab for metastatic Merkel cell carcinoma after chemotherapy ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
Nivolumab and ipilimumab combination for advanced skin cancer
Dr James Larkin - The Royal Marsden, London, UK
Nivolumab and ipilimumab combination for advanced skin cancer ( Dr James Larkin - The Royal Marsden, London, UK )
12 Apr 2017
Long-term clinical outcomes and analyses of atezolizumab for mTNBC
Prof Peter Schmid - Barts Cancer Institute, London, UK
Long-term clinical outcomes and analyses of atezolizumab for mTNBC ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
12 Apr 2017
Checkmate 067 - combined nivolumab and ipilimumab
Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Checkmate 067 - combined nivolumab and ipilimumab ( Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Durable responses to avelumab in patients with Merkel cell carcinoma
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors ( Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA )
12 Apr 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation